^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + OBT076 (Microtubule inhibitor, CD205-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.
Published date:
06/02/2022
Excerpt:
Two patients with low PD-L-1 expression received checkpoint inhibitor treatment with pembrolizumab after 2 and 5 cycles of OBT076, both patients experienced near complete response after only one to two cycles...OBT076 at 3.0mg/kg has shown favorable safety profile with manageable neutropenia. The preliminary efficacy has shown preliminary antitumoral single agent activity...The two patients who received a sequential administration of pembrolizumab after OBT076 showed major tumor activity.
DOI:
10.1200/JCO.2022.40.16_suppl.3028
Trial ID:
